Roche Holding AG PE Ratio 2012-2025 | RHHBY
Current and historical p/e ratio for Roche Holding AG (RHHBY) from 2012 to 2025. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Roche Holding AG PE ratio as of January 19, 2026 is 0.00.
| Roche Holding AG PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2026-01-16 | 54.25 | 0.00 | |
| 2025-06-30 | 40.76 | 0 | 0.00 |
| 2024-12-31 | 33.76 | 0 | 0.00 |
| 2024-06-30 | 33.55 | 0 | 0.00 |
| 2023-12-31 | 33.64 | 0 | 0.00 |
| 2023-06-30 | 35.47 | 0 | 0.00 |
| 2022-12-31 | 35.05 | 0 | 0.00 |
| 2022-06-30 | 37.35 | 0 | 0.00 |
| 2021-12-31 | 45.06 | 0 | 0.00 |
| 2021-06-30 | 40.97 | 0 | 0.00 |
| 2020-12-31 | 37.07 | 0 | 0.00 |
| 2020-06-30 | 36.68 | 0 | 0.00 |
| 2019-12-31 | 33.33 | 0 | 0.00 |
| 2019-06-30 | 28.77 | 0 | 0.00 |
| 2018-12-31 | 24.68 | 0 | 0.00 |
| 2018-06-30 | 21.94 | 0 | 0.00 |
| 2017-12-31 | 24.16 | 0 | 0.00 |
| 2017-06-30 | 24.32 | 0 | 0.00 |
| 2016-12-31 | 21.13 | 0 | 0.00 |
| 2016-06-30 | 24.40 | 0 | 0.00 |
| 2015-12-31 | 24.72 | 0 | 0.00 |
| 2015-06-30 | 25.15 | 0 | 0.00 |
| 2014-12-31 | 23.61 | 0 | 0.00 |
| 2014-06-30 | 25.91 | 0 | 0.00 |
| 2013-12-31 | 23.66 | 0 | 0.00 |
| 2013-06-30 | 20.85 | 0 | 0.00 |
| 2012-12-31 | 16.42 | 0 | 0.00 |
| 2012-06-30 | 14.06 | 0 | 0.00 |
| 2011-12-31 | 13.26 | 0 | 0.00 |
| 2011-06-30 | 13.07 | 0 | 0.00 |
| 2010-12-31 | 10.89 | 0 | 0.00 |
| 2010-06-30 | 10.20 | 0 | 0.00 |
| 2009-12-31 | 12.14 | 0 | 0.00 |
| 2009-06-30 | 9.82 | 0 | 0.00 |
| 2008-12-31 | 10.63 | $0.15 | 70.88 |
| 2008-06-30 | 12.44 | $0.15 | 82.90 |
| 2007-12-31 | 11.61 | $0.15 | 77.39 |
| 2007-09-30 | 12.27 | $0.15 | 81.83 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $345.602B | $68.726B |
| Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its operations through two segments ' Pharmaceuticals and Diagnostics.Pharmaceuticals: Key focus areas in this segment include Oncology, Virology, Inflammation, Metabolism and Neuroscience. Diagnostics: The Diagnostics Division operates in four segments ' Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics, and Roche Tissue Diagnostics. In September 2014, Roche acquired InterMune for $8.3 billion and added Esbriet to its portfolio. During the first quarter of 2018, Roche acquired Flatiron Health and Ignyta, Inc. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $981.687B | 47.22 |
| Johnson & Johnson (JNJ) | United States | $526.817B | 21.07 |
| AbbVie (ABBV) | United States | $378.839B | 22.68 |
| Novartis AG (NVS) | Switzerland | $304.907B | 16.16 |
| Novo Nordisk (NVO) | Denmark | $278.303B | 16.32 |
| Merck (MRK) | United States | $270.119B | 12.58 |
| Pfizer (PFE) | United States | $145.838B | 8.02 |
| Sanofi (SNY) | France | $113.633B | 10.99 |
| Bayer (BAYRY) | Germany | $50.890B | 8.93 |
| Innoviva (INVA) | United States | $1.454B | 7.28 |